false
English
Catalog
Best Practices and Research Advances in Thoracic O ...
First-Line Therapy for Advanced NSCLC without Driv ...
First-Line Therapy for Advanced NSCLC without Driver Mutations
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Tiziana Leal discusses first-line therapy for advanced non-small cell lung cancer (NSCLC) without driver mutations. Treatment selection involves assessing symptom burden, disease extent, histology, biomarkers, and patient preferences. For patients with high PD-L1 levels, immune checkpoint inhibitor monotherapy is typically used. Those with low or negative PD-L1 often receive a combination of chemotherapy and immunotherapy, or dual checkpoint inhibitors with or without chemotherapy. Key clinical trials (e.g., Keynote 024, Empower 110) show improved survival with these approaches. CTLA-4 inhibitors play a role in certain patient subsets, including those with specific molecular alterations.
Asset Subtitle
Ticiana Leal, MD
Keywords
NSCLC
immune checkpoint inhibitors
PD-L1
chemotherapy
CTLA-4 inhibitors
×
Please select your language
1
English
5
普通话
11
Dutch